Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV) : an open-label randomised controlled phase 3 trial
| Autor: | Hisham, Mehanna, Max, Robinson, Andrew, Hartley, Anthony, Kong, Bernadette, Foran, Tessa, Fulton-Lieuw, Matthew, Dalby, Pankaj, Mistry, Mehmet, Sen, Lorcan, O'Toole, Hoda, Al Booz, Karen, Dyker, Rafael, Moleron, Stephen, Whitaker, Sinead, Brennan, Audrey, Cook, Matthew, Griffin, Eleanor, Aynsley, Martin, Rolles, Emma, De Winton, Andrew, Chan, Devraj, Srinivasan, Ioanna, Nixon, Joanne, Grumett, C René, Leemans, Jan, Buter, Julia, Henderson, Kevin, Harrington, Christopher, McConkey, Alastair, Gray, Janet, Dunn, Mererid, Evans |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
Male
QR355 Squamous Cell Carcinoma of Head and Neck Papillomavirus Infections Cetuximab Antineoplastic Agents Chemoradiotherapy Kaplan-Meier Estimate Middle Aged Risk Assessment Drug Administration Schedule RC0254 Oropharyngeal Neoplasms Treatment Outcome Acute Disease Humans Female Radiotherapy Intensity-Modulated Cisplatin Neoplasm Staging |
| ISSN: | 0140-6736 |
| Popis: | Background The incidence of human papillomavirus (HPV)-positive oropharyngeal cancer, a disease affecting younger patients, is rapidly increasing. Cetuximab, an epidermal growth factor receptor inhibitor, has been proposed for treatment de-escalation in this setting to reduce the toxicity of standard cisplatin treatment, but no randomised evidence exists for the efficacy of this strategy. Methods We did an open-label randomised controlled phase 3 trial at 32 head and neck treatment centres in Ireland, the Netherlands, and the UK, in patients aged 18 years or older with HPV-positive low-risk oropharyngeal cancer (non-smokers or lifetime smokers with a smoking history of |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|